Editas Medicine Inc (NASDAQ:EDIT) CEO Katrine Bosley sold 8,333 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $36.18, for a total value of $301,487.94. Following the transaction, the chief executive officer now owns 1,338,898 shares of the company’s stock, valued at $48,441,329.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Katrine Bosley also recently made the following trade(s):
- On Tuesday, January 30th, Katrine Bosley sold 20,000 shares of Editas Medicine stock. The shares were sold at an average price of $38.79, for a total value of $775,800.00.
- On Tuesday, January 23rd, Katrine Bosley sold 3,338 shares of Editas Medicine stock. The shares were sold at an average price of $35.28, for a total value of $117,764.64.
- On Wednesday, January 3rd, Katrine Bosley sold 14,995 shares of Editas Medicine stock. The shares were sold at an average price of $34.15, for a total value of $512,079.25.
- On Friday, December 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $29.58, for a total value of $246,490.14.
Shares of Editas Medicine Inc (EDIT) traded down $0.77 on Monday, reaching $33.98. The company had a trading volume of 1,535,825 shares, compared to its average volume of 1,924,251. The company has a market capitalization of $1,576.36, a P/E ratio of -10.49 and a beta of 4.79. Editas Medicine Inc has a 12 month low of $13.12 and a 12 month high of $41.60. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12.
Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). The company had revenue of $6.28 million during the quarter, compared to the consensus estimate of $2.66 million. Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The firm’s quarterly revenue was up 553.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.59) earnings per share. sell-side analysts anticipate that Editas Medicine Inc will post -2.92 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the stock. IHT Wealth Management LLC bought a new stake in Editas Medicine in the second quarter worth $107,000. Great West Life Assurance Co. Can increased its stake in Editas Medicine by 519.9% in the third quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after purchasing an additional 4,159 shares during the period. Legal & General Group Plc increased its stake in Editas Medicine by 308.4% in the second quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after purchasing an additional 6,535 shares during the period. Royal Bank of Canada increased its stake in Editas Medicine by 4.1% in the second quarter. Royal Bank of Canada now owns 9,364 shares of the company’s stock worth $157,000 after purchasing an additional 372 shares during the period. Finally, Plancorp LLC purchased a new stake in Editas Medicine in the fourth quarter worth $235,000. Institutional investors own 64.45% of the company’s stock.
A number of research firms have recently commented on EDIT. Zacks Investment Research downgraded Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cann restated a “hold” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Cowen restated a “buy” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. SunTrust Banks upgraded Editas Medicine from a “hold” rating to a “buy” rating and raised their price target for the stock from $17.00 to $45.00 in a research report on Tuesday, January 23rd. Finally, BidaskClub upgraded Editas Medicine from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $30.73.
ILLEGAL ACTIVITY WARNING: This piece was reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thestockobserver.com/2018/02/05/editas-medicine-inc-edit-ceo-sells-301487-94-in-stock.html.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.